Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Multiple Myeloma 43Prostatic Neoplasms 41Carcinoma, Non-Small-Cell Lung 36Breast Neoplasms 34Lymphoma 28Leukemia, Myeloid, Acute 25Lymphoma, Non-Hodgkin 21Melanoma 18Colorectal Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Ovarian Neoplasms 15Lung Neoplasms 15Hodgkin Disease 15Hematologic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasms 13Neoplasm Metastasis 13Myelodysplastic Syndromes 13Sarcoma 12Leukemia, Lymphocytic, Chronic, B-Cell 12Wilms Tumor 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Burkitt Lymphoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Leukemia 9Glioma 9Fallopian Tube Neoplasms 9

Interventions

sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Meningeal Neoplasms × 30 days × Clear all
NCT04250545 2026-05-26

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled 14 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡